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PURPOSE. To assess the relationship between macular pigment
optical density (MPOD) and blood markers for antioxidant
defense in otherwise healthy volunteers.
METHODS. Forty-seven healthy volunteers were subjected to
blood analysis to detect the level of circulating glutathione in
its reduced (GSH) and oxidized (GSSG) forms. The level of
MPOD was measured using heterochromatic flicker photome-
try. Systemic blood pressure (BP) parameters, heart rate (HR),
body mass index (BMI), and plasma levels of total, HDL, and
LDL cholesterol and triglycerides (TGs) were also determined.
RESULTS. A simple correlation model revealed that the level of
MPOD correlated significantly and positively with both GSH
(P  0.001) and t-GSH (P  0.001) levels but not with those of
GSSG (P  0.05). Age, sex, systemic BP parameters, HR, BMI,
and plasma levels of cholesterol and TGs did not have any
influence on either MPOD or glutathione levels (all P  0.05).
In addition, a forward stepwise multiple regression analysis
showed MPOD to have a significantly and independent corre-
lation with GSH levels (  0.63; P  0.001).
CONCLUSIONS. In otherwise healthy older individuals, there is a
positive correlation between local and systemic antioxidant
defense mechanisms. (Invest Ophthalmol Vis Sci. 2011;52:
5029–5033) DOI:10.1167/iovs.11-7240
Among environmental, nutritional, and genetic risk factorsinvolved in the etiology of AMD, high levels of oxidative
stress, a harmful state defined by the presence of pathologic
levels of reactive oxygen species (ROS) relative to the antiox-
idant defense, have been said to play a role.1–3 In healthy
subjects, local retinal protection against free radicals is aided
by the presence of macular pigment (MP), which is comprised
of the carotenoid lutein and its isomers zeaxanthin4 and meso-
zeaxanthin.5 It has been suggested that these xanthophylls play
a similar role in humans as in plants—that is, as antioxidants
and screeners of high-energy blue light.6 In this way, MP may
prevent light-initiated oxidative damage to the retina and there-
fore protect against subsequent AMD.7 Indeed, the absorbance
spectrum of MP peaks at 460 nm and it is thought to act as a
broadband filter, reducing the sensitivity of the macular region
to short wavelength light, which is most damaging in the 440
to 460 nm range.8,9 In addition, the fact that lutein and zeax-
anthin have been found in higher concentrations in the rod
outer segments of the perifoveal retina than the peripheral
retina lends support to their proposed protective role against
AMD.10 These carotenoids are able to quench singlet oxygen (a
potent oxidant),11 scavenge ROS,12 limit the peroxidation of
membrane phospholipids,13 and reduce lipofuscin forma-
tion.14
In addition to local retinal damage, high levels of oxidative
stress also induces vascular changes that confer a background
for circulatory disturbances in the systemic macro- and micro-
circulation that are also present in AMD patients.15,16 Indeed,
it has been shown that in addition to ocular vascular compli-
cations, AMD patients are at higher risk for developing coro-
nary heart disease (CHD) and stroke17,18; moreover, they also
are more likely to have a decreased survival rate compared to
the general age-matched population.19 It has been shown that
AMD patients have lower levels of circulating glutathione
(GSH), a major low-molecular weight antioxidant peptide20; in
addition to a direct vascular effect, this deficiency could also
result in low bioavailability of the vasodilatory molecule nitric
oxide (NO)21 and endothelial dysfunction, a condition known
to precede both metabolic and cardiovascular diseases but also
ocular circulatory disturbances.
It has been reported that dietary intake of lutein and zeax-
anthin augument the level of MP with a possible positive effect
on AMD prevention and prognosis.22,23 In addition, carote-
noid-rich food intake has a positive influence on systemic
antioxidant status in healthy persons.24 The aim of the present
study was to determine whether there is a relationship be-
tween local and systemic antioxidant defense markers in older
volunteers free of either ocular or systemic diseases.
MATERIALS AND METHODS
Study Sample
Healthy subjects recruited by advertising at Aston University, Birming-
ham, United Kingdom were considered for inclusion in this prospec-
tive study. Ethical approval was sought from the local ethics commit-
tee, and written informed consent was obtained from all participants
before enrolling into the study. The study was designed and conducted
according to the principles of the Declaration of Helsinki.
Exclusion criteria were smoking, a history of any chronic systemic
disease with presumed abnormal circulating GSH levels, including
autoimmune diseases,25 alcoholic liver disease,26 cancer,27 and diabe-
tes mellitus.28 In addition, subjects were also excluded if they had
cardiovascular or cerebrovascular disease, coronary artery disease
(heart failure, arrhythmia, stroke, or transient ischemic attacks), inflam-
matory conditions (rheumatoid arthritis and systemic lupus erythema-
tosus), or were receiving hormone replacement therapy or antioxi-
dant/vitamin/iron supplements.
Potential participants were screened for ocular diseases by an
ophthalmologist and patients with ocular diseases, such as cataracts,
glaucoma, and AMD, were also excluded from the study. Retinal
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photographs were taken using a digital camera (Zeiss FF 450 Plus
Fundus Camera; Carl Zeiss Meditec, Inc, Jena, Germany) and the
presence or absence of drusen or pigmentary changes associated with
AMD was assessed before inclusion in the study. In addition, potential
participants were required to complete a questionnaire on their gen-
eral health, physical activity, and alcohol consumption. The question-
naire included a detailed investigation on the daily intake of fruit and
vegetables and other nutrients.
Investigations
Subjects were instructed to fast after 9 PM on the evenings before
being tested. On the morning of the test, subjects were requested to
have only a light breakfast, such as toast. They were also asked to avoid
any cooked breakfast, meat, cereal, fresh fruits, or fruit juice.29 In
addition, subjects were asked to abstain from caffeinated beverages
and chocolate and from alcohol for at least 2 hours before the visit. The
height and weight of the participants was measured and the body mass
index (BMI) was calculated (as kg/m2).
Blood Pressure Measurement
Blood pressure (BP) was measured in each subject in the morning
between 8 AM and 9 AM with a BP monitor (UA-779; A7D Instruments
Ltd., Oxford, UK). In preparation for this measurement, each subject
rested in a sitting position for approximately 10 minutes in a quiet
room to achieve sufficient mental and physical calm. The systolic BP
(SBP) and diastolic BP (DBP) were measured three times (1 minute
apart). The average readings for SBP and DBP were then used to
calculate the mean BP (MBP) using the formula: MBP  2/3DBP 
1/3SBP.
Blood Sampling and Analyses
All blood samples were obtained by a qualified phlebotomist between
9 AM and 10 AM.
Routine Tests
Fasting, triglycerides (TG), and total and high-density lipoprotein (HDL)
cholesterol levels were measured automatically using a Reflotron Desktop
Analyzer (Roche Diagnostics, Welwyn Garden City, UK).
Blood Sampling for GSH Analyses
Seven milliliters of blood was collected in EDTA tubes (to prevent
oxidation)30 by venipuncture to the antecubital vein using a butterfly
needle and syringe to avoid hemolysis.20 The blood (30 L) was then
transferred into centrifuge tubes for the initial processing. GSH was
released from the blood cells by protein precipitation and cellular
disruption achieved by addition of 33.3 L of 5-sulfosalicylic acid
(SSA), 1 g/mL within 10 minutes from the blood collection.31 The
addition of acid minimizes artifactual sample oxidation and removes
interfering protein thiols.
Each sample was then diluted with 936.7 L sodium phosphate
buffer (pH 7.5) and the content of each tube was rapidly centrifuged
at 13,000 rpm for 5 minutes. Small amounts (150 L) of supernatant
were collected into clean centrifuge tubes and immediately cooled at
70°C. Samples stored at this temperature are stable for at least 2
months and can be transported on dry ice without deterioration.32 In
our hands, GSH loss is  5% over this time period.
GSH Assay
The total GSH levels (t-GSH) were assessed by the GSH reductase-
DTNB (5.5 dithiobis-2-nitrobenzoic acid) recycling procedure, as de-
scribed in previous studies.30,33,34 Standards were prepared from 0 to
80 M in 20-M increments using 10 mM GSH solution. The standards
contained the same final concentrations of SSA as the samples. To each
well of a 96-well plate, NADPH (0.3 mg/mL), dissolved in 150 L of 125
mM sodium phosphate with 6.3 mM EDTA pH 7.5, also known as daily
buffer, 50 L of DTNB solution, and 25 L of standards or samples
were added in quadruplicate and the plate was incubated at 37°C for
3 minutes. Finally, 25 L of GSH reductase (GSR) was added to the
previous mixture and the plate was read at 410 nm using a 96-well
plate reader. A standard curve of GSH was then generated using a linear
regression program (Microsoft Excel; Microsoft, Redmond, WA) as
previously reported.34
GSSG Assay
GSSG levels were assessed using a GSH reductase-DTNB recycling
assay.30 The reagents used in this assay were those already described
above for GSH assay and, in addition, triethanolamine (TEA) and 2-vinyl
pyridine (2-VP). TEA prevents a high local pH and oxidation, while
2-VP is used for derivitization of GSH. GSSG standards were prepared
from 0 to 10 M in 1-M increments; 100 L of standards and samples
were transferred into separate centrifuge tubes and 2 L 2-VP was
added to each tube. TEA was then used to adjust the pH of the
standards/samples to pH 7.5. The assay was carried out as for GSH
assay described above. Finally, a standard curve of GSSG was then
generated using a linear regression program (Microsoft Excel) as pre-
viously reported.34
The GSH levels [t-GSH – (2  GSSG)] and the redox index (defined
as the GSH/GSSG ratio) were then calculated.
Macular Pigment Optical Density Measurement
Macular pigment optical density (MPOD) was determined using the
MPS 9000 (also known as the M:Pod and the QuantifEYE; Topcon
House, Berkshire, UK). This device measures MPOD using heterochro-
matic flicker photometry, in which subjects respond to the appearance
of flicker as the alternation rate is decreased at 6 Hz per sec from a
starting level of 60 Hz.35 Because this is above the critical flicker fusion
frequency for the test conditions, subjects do not perceive any flicker
initially. A sequence of blue-green ratios is used and these are inverse-
yoked to ensure that overall luminance remains constant. The device
determines each observer’s sensitivity to flicker before the main part of
the test. This technique is well documented,36 and the reliability of this
particular instrument has also been assessed by our group.37
The eye not being tested was occluded and participants wore their
habitual refractive correction (a trial frame and lenses were used when
necessary). The central target is a 1° circular stimulus composed of
blue (465 nm) and green (530 nm) LEDs. For the foveal (central) test,
the observer looked directly at the stimulus while the alternation rate
between the blue and green was ramped down from 60 Hz. At the point
when they first detected flicker, the observer pressed a response button
and this plotted a point on a graph that was visible to the operator on
a computer screen. Once the flicker had been perceived, the process
started again. The first five responses were used to ascertain the flicker
sensitivity of the subject. The observer is asked to respond to a series
of green-blue ratios until a V-shaped curve is plotted on the computer
screen. The minimum point on the curve corresponds to equilumi-
nance of the blue and green lights. The process was then repeated for
the peripheral test, where the subject’s gaze was directed to a larger
red target, 8° eccentric from the central spot. The difference between
the central and peripheral minima is used by an internal algorithm to
calculate the MPOD. Each subject was given a practice run of the test,
and the results were screened such that if an appropriate V-shaped
curve was not obtained, the test was repeated.
Statistical Analysis
Statistical analysis was performed using Statistica for Windows (version
9.0; StatSoft Inc., Tulsa, OK). Data are expressed as mean  SD. Pear-
son’s correlation test and a forward stepwise multiple regression anal-
ysis were performed to test the relationship between the measured
variables. P values  0.05 were considered statistically significant.
RESULTS
Sixty-one healthy subjects with similar dietary habits were
selected for inclusion. However, after the evaluation of the
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fundus photographs and eliminating those with potential mac-
ular changes, only 47 healthy subjects (29 women and 18 men)
were included in the final analysis. The characteristics of the
study participants are provided in Table 1. Table 2 shows the
anthropometric and vascular parameters determined by sex.
Men exhibited higher SBP (P 0.018) and DBP (P 0.01) and
lower levels of HDL cholesterol (P  0.002) than women.
However, MPOD and systemic oxidative markers were similar
between the sexes (all P  0.05).
A simple correlation model revealed that the level of MPOD
correlated significantly and positively with both blood GSH
(r  0.64; P  0.001) and t-GSH (r  0.63; P  0.001) levels
but not with those of GSSG (P  0.05). Age, systemic BP
parameters, BMI, and plasma levels of cholesterol and TGs did
not have any influence on either MPOD or blood GSH levels (all
P  0.05). A stepwise multiple regression analysis revealed
MPOD levels to be independently, significantly, and positively
correlated with blood GSH levels (  0.64; P  0.001; Fig. 1).
DISCUSSION
At the retinal level, oxidative stress results in degeneration and
death of the RPE and photoreceptors.38 Because these retinal
structures are not able to regenerate after such insult, protec-
tive mechanisms have developed to ensure a minimal local
effect of free radicals.39 Indeed, MP is present in the rod outer
segments, and RPE and its specific spectral absorption and the
presence of lutein and zeaxanthin have enabled it with strong,
protective antioxidant properties. There are several methods
for measuring the level of MP, including various subjective
psychophysical and objective optical techniques.39 One of
these subjective methods is represented by the heterochro-
matic flicker photometry that involves the calculation of MPOD
based on the luminance ratio of short wavelength blue light
presented in the central retina (where is assumed to be par-
tially absorbed by the MP) compared to that presented at a
more peripheral retinal point, where MP levels are assumed to
be minimal.40 This method offers a good measure of the MPOD
levels and is widely available in practice. By using this method,
our analysis has shown for the first time an independent,
significant, and positive relationship between MPOD and blood
GSH levels. At this stage, more research is necessary to provide
better knowledge of the exact mechanisms responsible; nev-
ertheless, we can still propose a few hypotheses. It has been
reported that the dietary intake of carotenoids had an influence
not only on the level of MP22,23 but also on the systemic
circulating antioxidant markers.24 In addition, exogenous sup-
ply of GSH protects the RPE against oxidative damage.41 Al-
though the individuals included in the present study did not
receive either a special diet rich in carotenoids nor GSH or
other antioxidant supplementation, the aforementioned results
simply show that a relationship between local and systemic
protective mechanisms—such as that found by our study—
could exist. Consequently, although novel, our results should
not be surprising.
Other mechanisms can also be speculated. Melatonin, a
neurohormone that is secreted by retinas and the pineal gland,
has an influence on the RPE and controls the amount of light
reaching the photoreceptors; in addition, it also acts as potent
antioxidant at both the ocular and systemic level and, in such
capacity, it has been advocated to reduce the risk for pathol-
ogies associated with high oxidative damage, such as AMD42
and cardiovascular disease.43 In addition, melatonin also acti-
vates other antioxidant defenses including GSH peroxidase
(GPx), an enzyme that uses GSH as a substrate to eliminate
ROS.44,45 Melatonin production could be affected by aging as
the pupil diameter and the light absorption through the crys-
talline lens changes with age progression.46–48 Consequently,
aging contributes to an abnormal melatonin production and
TABLE 1. Characteristics of the Study Participants
Age, y
( SD) Sex, F:M
SBP, mm Hg
( SD)
DBP, mm Hg
( SD)
BMI, kg/m2
( SD)
Total
Cholesterol,
mmol/L ( SD)
HDL
Cholesterol,
mmol/L ( SD)
LDL
Cholesterol,
mmol/L ( SD)
TG, mmol/L
( SD)
50  9 29:18 118  13 73  9 25.20  4.15 4.46  0.82 1.29  0.33 2.61  0.80 1.23  0.62
BMI, body mass index; DBP, diastolic blood pressure; F, female; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, male; SBP,
systolic blood pressure; TG, triglycerides.
TABLE 2. Measured Parameters for Men and Women
Female Male P
Age, y ( SD) 49  9 50  8 0.05
MPOD ( SD) 0.46  0.18 0.47  0.12 0.05
TG, mmol/L ( SD) 1.16  0.65 1.35  0.58 0.05
Total cholesterol, mmol/L
( SD)
4.52  0.69 4.37  1.00 0.05
HDL cholesterol, mmol/L
( SD)
1.40  0.29 1.11  0.30 0.002
LDL cholesterol, mmol/L
( SD)
2.58  0.75 2.65  0.89 0.05
BMI, kg/m2 ( SD) 24.48  4.06 26.37  4.13 0.05
SBP, mm Hg ( SD) 115  12 124  12 0.018
DBP, mm Hg ( SD) 70  9 77  8 0.010
HR, bpm ( SD) 72  7 69  8 0.05
t-GSH, mol/L ( SD) 1177  564 1089  416 0.05
GSSG, mol/L ( SD) 88  44 78  51 0.05
GSH, mol/L ( SD) 1002  526 932  383 0.05
Redox index, GSH:GSSG
( SD)
11  7 12  6 0.05
BMI, body mass index; DBP, diastolic blood pressure; GSH, re-
duced glutathione; GSSG, oxidized glutathione; HDL, high-density li-
poprotein; HR, heart rate; LDL, low-density lipoprotein; MPOD, mac-
ular pigment optical density; SBP, systolic blood pressure; TG,
triglycerides; t-GSH, total GSH.
FIGURE 1. The correlation between the levels of macular pigment
optical density and reduced glutathione in the study population (P 
0.001).
IOVS, August 2011, Vol. 52, No. 9 MPOD and Oxidative Stress 5031
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 08/15/2018
also decreases antioxidant defense, which in turn will result in
accelerated aging processes with various effects throughout
the human body, including the eye. Although measuring mel-
atonin levels was not an aim in the present research, we could
still hypothesize that a link between ocular and systemic anti-
oxidant mechanisms could also be established indirectly via
melatonin. This hypothesis should, however, be tested in var-
ious age groups. In addition, other mechanisms are most cer-
tainly involved and should be further researched using more
complex analyses. The role of antioxidants proven to have a
link to both macular pigment and circulating GSH levels should
also be researched. Nevertheless, as previously emphasized,
the positive correlation between the levels of MPOD and GSH
seen in our study probably only reveal that, in healthy individ-
uals, the antioxidant defense mechanisms present at various
levels act in the same direction to protect the body against
harmful effects of ROS. However—and maybe most importantly—
our research points toward the necessity of studying various
normal relationships between ocular and systemic protective
mechanisms against diseases with multiple etiologies and com-
plications, such as AMD. In this way, we could understand
better results that are reported after various pathologic
changes have already occurred. Reducing the risk for AMD is
important, and strengthening natural bodily mechanisms that
are at their best in healthy individuals seems to be one of the
possible approaches.
Although some studies report sex differences in plasma
GSH levels,49 others did not confirm it in either plasma or
blood GSH.50 In agreement with later studies, we also could
not find any difference between men and women with respect
to blood GSH levels. It is possible that the various methods
used for GSH assay are responsible for this lack of consistency
in the results. There is no general agreement as to what
method is best for analyzing circulating GSH. In the present
study, we used a validated method for measuring blood levels
of GSH and GSSG30,33,34 that is known to minimize variability
from more complicated sample preparation steps associated
with methods measuring plasma GSH.50 In addition, to avoid
variations and GSH loss, we have paid particular attention to
blood collection, initial processing, and storage. Blood samples
were collected at the same time (between 9 AM and 10 AM)
and processed in the same way and time interval from collec-
tion in all individuals. Moreover, incorporation of GSR in our
assay confers it specificity to GSH.
Study Limitations
As previously emphasized, our research included only patients
over 40 years of age that were carefully selected to exclude
macular changes or other ocular pathologies as well as sys-
temic chronic disease and various therapeutic interventions.
We have also excluded smokers and individuals taking any
antioxidant supplements. This careful selection has limited the
number of individuals included in the final analysis. It is pos-
sible that the relationship between MPOD and circulating GSH
level is different not only in various age groups but also in
individuals with additional risk factors for AMD and/or vascular
disease. Moreover, individuals having a diet either lacking or
very rich in carotenoids or receiving various supplements as
well as patients suffering from AMD with or without vascular
complications may display very different results. More studies
to include larger and more various populations to cover the
many possible confounders that have been either missed or
intentionally avoided in the present study are warranted.
In conclusion, our study has shown for the first time that in
older, healthy, nonsmoking individuals, MPOD correlates with
whole blood levels of GSH. Because assays for measuring sys-
temic levels of antioxidant molecules are complex and need
specialized laboratories, it is tempting to propose that a simple
MPOD assessment could be used as surrogate indicator of the
individual’s systemic capacity of dealing with the damaging
effect of free radicals and, consequently, of their risk for de-
veloping chronic ocular and/or systemic pathologies. Never-
theless, this assumption should be verified in larger studies,
and the clinical significance of associations such as the one
reported by our research should be carefully analyzed.
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